News search

The most potent genetic risk factor for Alzheimer disease, APOE4, is associated with an elevated risk of developing subclinical atherosclerosis in middle age, whereas the Alzheimer-protective variant of the same gene, APOE2, protects against subclinical atherosclerosis

The ImnovAth project seeks an innovative approach to treat atherosclerosis

Dr. Carla Rothlin is Dorys McConnell Duberg Professor of Immunobiology and Professor of Pharmacology at the Yale School of Medicine, and co-leader of the Cancer Immunology Programme at Yale Cancer Centre. She studied biochemistry and pharmacology at the University of Buenos Aires, where she also undertook her postgraduate research under the direction of Dr. Ana Belén Elgoyhen, focussing on nicotinic receptors expressed in the inner ear. Later, she completed her doctorate and moved to San Diego to join Dr. Greg Lemke’s laboratory at the Salk Institute for Biological Studies. In 2009, Dr. Rothlin was named Assistant Professor in Immunobiology at Yale Medical School

CNIC and the i+12 Institute co-lead one of the working groups of this initiative.

Atherosclerosis, previously believed to be an irreversible progressive disease, can be reversed if risk factors are contolled early enough

This work is of fundamental importance for understanding the immune system and its reactions